Glenmark Pharmaceuticals Limited — Q2 FY25
Glenmark's Q2 FY25 consolidated revenue grew 7.1% YoY to INR 3,434 crore, driven by strong India (13.9% YoY) and Europe (14.6% YoY) performance, partially offset by a 1.2% decli...
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY25
US recovery expected in H2 FY25
Management expects US business to recover in the second half of FY25, driven by respiratory product approvals and Monroe facility restart.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1